Targeting epidermal growth factor receptor in the management of lung cancer.

Abstract

The epidermal growth factor receptor (EGFR) mutation is a potent oncogenic driver that accounts for carcinogenesis and tumor growth of pulmonary adenocarcinoma. Targeting EGFR with tyrosine kinase inhibitors (TKIs) is highly effective in terms of tumor response rate, progression-free survival (PFS), and quality of life. Multiple randomized studies have confirmed the superiority of EGFR TKIs over platinum-based chemotherapy and established EGFR TKIs as standard first-line therapy for patients with EGFR mutation-positive non-small cell lung cancer (NSCLC). However, almost all patients will develop resistance to EGFR TKIs and post progression therapy may include a combination of local therapy, systemic chemotherapy, and second-generation EGFR TKIs.

• Authors: Tony S K Mok, Kirsty Lee, Linda Leung
• Journal: Seminars in oncology (Semin Oncol) Vol. 41 Issue 1 Pg. 101-9 (Feb 2014) ISSN: 1532-8708 [Electronic] United States
• PMID: 24565584 (Publication Type: Journal Article, Review)
• Copyright: Copyright © 2014 Elsevier Inc. All rights reserved.

Chemical References

• Antineoplastic Agents
• Protein Kinase Inhibitors
• EGFR protein, human
• ErbB Receptors

Topics

• Animals
• Antineoplastic Agents (therapeutic use)
• ErbB Receptors (antagonists & inhibitors, metabolism)
• Humans
• Lung Neoplasms (drug therapy, metabolism)
• Molecular Targeted Therapy
• Protein Kinase Inhibitors (therapeutic use)